We are live on ! Find out more
SER icon

Serina Therapeutics

34 hedge funds and large institutions have $1.91M invested in Serina Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

13% more funds holding

Funds holding: 3034 (+4)

0.01% more ownership

Funds ownership: 0.36%0.37% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

42% less capital invested

Capital invested by funds: $3.29M → $1.91M (-$1.37M)

Holders
34
Holders Change
+4
Holders Change %
+13.33%
% of All Funds
0.5%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
6
Reduced
8
Closed
1
Calls
Puts
Net Calls
Net Calls Change

SER Hedge Fund Activity: Q4 2023 in Review

34 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q4 2023, worth a combined $1.91M — down 42% from $3.29M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SER positions and 1 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Sigma Planning Corp, adding an estimated $55K. The largest seller was Summit X LLC, cutting an estimated $7.58K.

  • 34 institutional investors held Serina Therapeutics (SER) as of Q4 2023, up from 30 in Q3 2023.
  • Funds reported $1.91M of Serina Therapeutics stock for Q4 2023, down 42% quarter-over-quarter.
  • 5 funds opened new Serina Therapeutics positions in Q4 2023 and 1 closed out, a net change of +4 holders.
  • The largest Serina Therapeutics buyer in Q4 2023 was Sigma Planning Corp, an estimated $55K added.
  • The largest Serina Therapeutics seller in Q4 2023 was Summit X LLC, an estimated $7.58K sold.

Based on aggregated 13F filings for Q4 2023.